Results 21 to 30 of about 382,920 (355)

GPRC5D-Targeted CAR T Cells for Myeloma

New England Journal of Medicine, 2022
BACKGROUND B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapies have generated responses in patients with advanced myeloma, but relapses are common. G protein–coupled receptor, class C, group 5, member D (GPRC5D) has
S. Mailankody, Sean M. Devlin, Jonathan Landa, Karthik Nath, C. Diamonte, Elizabeth J Carstens, D. Russo, Romany Auclair, Lisa Fitzgerald, Briana Cadzin, Xiuyan Wang, D. Sikder, B. Senechal, Vladimir P Bermudez, Terence J. Purdon, K. Hosszu, D. McAvoy, Tasmin Farzana, E. Mead, Jessica A. Wilcox, B. Santomasso, G. Shah, U. Shah, N. Korde, A. Lesokhin, C. Tan, M. Hultcrantz, H. Hassoun, M. Roshal, F. Şen, Ahmet Dogan, O. Landgren, S. Giralt, Jae H. Park, Saad Z. Usmani, I. Rivière, R. Brentjens, Eric L Smith   +37 more
semanticscholar   +1 more source

Epidemiology, Staging, and Management of Multiple Myeloma

Medical Science, 2021
Multiple myeloma (MM) is a plasma cell disorder that is on the rise throughout the world, especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2% of cancer diagnoses and over 2% of cancer deaths (more than double the ...
S. Padala, Adam Barsouk, Alexander Barsouk, Prashanth Rawla, Anusha Vakiti, R. Kolhe, V. Kota, Germame Ajebo   +7 more
semanticscholar   +1 more source

Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution

Blood Cancer Journal, 2022
From January 1970 to December 2018, 1304 patients were diagnosed with multiple myeloma (MM) at our institution and 256 (19.6%) had plasmacytomas (Ps) (paraskeletal –PPs- 17.6%, extramedullary –EMPs-1.9%).
Raquel Jiménez-Segura, Laura Rosiñol, Ma Teresa Cibeira, Carlos Fernández de Larrea, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, Esther Bladé, David F. Moreno, Aina Oliver-Caldés, Joan Bladé   +9 more
doaj   +1 more source

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

Nature Communications, 2021
BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and durable responses in multiple myeloma. However, relapse following therapy is frequently observed, and mechanisms of resistance remain ill-defined.
M. Samur, M. Fulciniti, Anil Aktas Samur, A. Bazarbachi, Y. Tai, R. Prabhala, A. Alonso, A. Sperling, T. Campbell, F. Petrocca, K. Hege, S. Kaiser, H. A. Loiseau, K. Anderson, N. Munshi   +14 more
semanticscholar   +1 more source

Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma

Blood Cancer Journal, 2022
Interaction of plasmacytoid dendritic cells (pDCs) with multiple myeloma (MM) cells, T- or NK-effector cells in the bone marrow (BM) microenvironment induces tumor cell growth, as well as inhibits innate and adaptive immune responses.
Arghya Ray, Yan Song, Ting Du, Leutz Buon, Yu-Tzu Tai, Dharminder Chauhan, Kenneth C. Anderson   +6 more
doaj   +1 more source

The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma

Journal of Hematology & Oncology, 2020
Background Multiple Myeloma (MM) is a hematological malignancy with genomic heterogeneity and poor survival outcome. Apart from the central role of genetic lesions, epigenetic anomalies have been identified as drivers in the development of the disease ...
Samrat Roy Choudhury, Cody Ashby, Ruslana Tytarenko, Michael Bauer, Yan Wang, Shayu Deshpande, Judith Den, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Faith E. Davies, Frits van Rhee, Gareth J. Morgan, Brian A. Walker   +13 more
doaj   +1 more source

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma

Nature Communications, 2021
Progression from asymptomatic smoldering multiple myeloma (SMM) to symptomatic Multiple Myeloma occurs at different rates in different patients. Here, the authors report fewer NRAS and FAM46C mutations and adverse translocations in SMM compared to MM ...
Eileen M. Boyle, Shayu Deshpande, Ruslana Tytarenko, Cody Ashby, Yan Wang, Michael A. Bauer, Sarah K. Johnson, Christopher P. Wardell, Sharmilan Thanendrarajan, Maurizio Zangari, Thierry Facon, Charles Dumontet, Bart Barlogie, Arnaldo Arbini, Even H. Rustad, Francesco Maura, Ola Landgren, Fenghuang Zhan, Frits van Rhee, Carolina Schinke, Faith E. Davies, Gareth J. Morgan, Brian A. Walker   +22 more
doaj   +1 more source

How should multiple myeloma research change in a patient-oriented world? Findings and lessons from the pan-Canadian myeloma priority setting partnership

Research Involvement and Engagement, 2023
Background Over the last decade there has been considerable research into the treatment, management, and quality of life of people living with multiple myeloma.
Sarah Bridges, Samantha Fowler, Lauren McLaughlin, Marc Robichaud, Barbara Ridgway, Donna Reece, Kevin Song, Lorelei Dalrymple, Robin Sully, Sharon Nason, Suzanne Rowland, Trish MacDonald, William Paine, Adrienne Gulliver, Anthony Reiman   +14 more
doaj   +1 more source

The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states

Nature Communications, 2022
Spatially and temporally resolved data can improve our understanding of evolution and treatment resistance in multiple myeloma (MM). Here, the authors analyse spatial and longitudinal heterogeneity in MM patients using multi-region sequencing, and ...
Leo Rasche, Carolina Schinke, Francesco Maura, Michael A. Bauer, Cody Ashby, Shayu Deshpande, Alexandra M. Poos, Maurizio Zangari, Sharmilan Thanendrarajan, Faith E. Davies, Brian A. Walker, Bart Barlogie, Ola Landgren, Gareth J. Morgan, Frits van Rhee, Niels Weinhold   +15 more
doaj   +1 more source

Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

American journal of hematology/oncology, 2020
Multiple myeloma accounts for approximately 10% of hematologic malignancies.
S. Rajkumar
semanticscholar   +1 more source